Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
EPIOXA HD/EPIOXA KIT is a riboflavin 5-phosphate ophthalmic solution approved by the FDA in October 2025 for use via topical eye drops. The mechanism of action and specific indications are not publicly disclosed in available data, but the formulation targets ocular conditions treatable with riboflavin-based therapy. This represents Glaukos' entry into the ophthalmology market with a novel ophthalmic delivery system.
With LOE approaching in 2028 and moderate competitive pressure (25% intensity), the brand team faces a compressed commercial window and will likely prioritize rapid market penetration and differentiation strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on EPIOXA HD/EPIOXA KIT at Glaukos? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on EPIOXA HD offers exposure to a newly approved ophthalmic specialty product with an accelerated commercial timeline and impending LOE pressure. Career growth is concentrated in commercial execution, market access problem-solving, and rapid account building in a niche specialty segment.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo